|
시장보고서
상품코드
1813899
미국의 신경학 임상시험 시장 규모, 점유율, 동향 분석 보고서 : 단계별, 시험 디자인별, 적응증별, 밸류체인별, 부문별 예측(2025-2033년)U.S. Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design, By Indication, By Indication by Study Design, By Indication by Phase, By Value Chain, And Segment Forecasts, 2025 - 2033 |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
미국의 신경학 임상시험 시장 요약
미국의 신경학 임상시험 시장 규모는 2024년 25억 3,000만 달러로 평가되었습니다. 2033년에는 44억 7,000만 달러에 달하고, 2025-2033년 연평균 6.59% 성장할 것으로 예측됩니다.
미국의 신경학 임상시험 시장의 성장 원동력은 신경과학의 눈부신 발전, 의료비 지출 증가, 복잡한 신경 질환에 대한 표적 치료의 중요성입니다.
미국의 신경학 임상시험 산업의 성장을 가속하는 다른 요인으로는 환자 인식 증가, 희귀질환 치료제 및 획기적인 치료제에 대한 규제 당국의 지원, 신경학 연구개발에 대한 투자 증가 등을 들 수 있습니다. 신경퇴행성 질환의 발병률 증가는 잘 구축된 임상연구 인프라에 힘입어 미국은 신경학 임상시험의 중요한 중심지로 자리매김하고 있습니다. 또한, 민관 양 부문의 자금 지원과 제약사, CRO(임상시험수탁기관), 학계의 전략적 제휴가 시험 일정 단축과 시험 효율성 향상에 중요한 역할을 하며 시장을 더욱 뒷받침하고 있습니다.
알츠하이머병, 파킨슨병, 다발성 경화증, 간질, 각종 희귀 신경증후군의 유병률 증가로 인해 새로운 치료 옵션에 대한 요구가 높아지면서 임상시험이 증가하고 있습니다. 이러한 연구들은 초기 단계부터 후기 단계까지 진행되고 있으며, 보다 진전된 프로그램에서는 질병 변형 요법, 신경 보호제, 유전자 기반 중재에 집중하고 있습니다. 또한, 제약사 및 생명공학 기업들은 임상시험 프로토콜 관리, 수행 속도 향상, 임상시험의 업무 효율성을 높이기 위해 사내 CRO 기능을 확대하고 있습니다. 또한, 신경학에 특화된 임상시험 기관이 늘어나면서 환자 모집의 정확성을 높이고, 임상시험의 질을 최적화하며, 등록 기간을 단축하고 있습니다. 사내 역량과 임상시험 수행기관의 전문성을 결합하여 국내 신경계 임상시험의 규모와 수행률을 높이고 있습니다.
또한, 시장 진출기업들은 보다 광범위한 환자 참여와 신속한 데이터 수집을 가능하게 하는 분산형 및 하이브리드 임상시험 모델을 채택하는 추세로 전환하고 있습니다. 또한, 첨단 신경영상 기술, 바이오마커 기반 진단, AI 기반 환자 선택 도구의 도입이 진행되면서 검사의 정확성과 결과 예측 가능성이 높아지고 있습니다. 또한, 많은 바이오 제약사들이 신경학 연구 포트폴리오와 시설 네트워크를 확장하여 지리적 범위를 넓히고, 규제 당국의 승인을 신속하게 처리하고, 의료 서비스가 부족한 지역의 환자들의 미충족 수요를 충족시키기 위해 신경학 연구 포트폴리오와 시설 네트워크를 확장하고 있으며, 이는 미국의 신경학 임상시험 시장을 더욱 촉진하고 있습니다. 미국의 신경학 임상시험 시장을 더욱 활성화하고 있습니다.
이처럼 신경학 임상시험 시장은 의료비, 노동 생산성, 환자의 전반적인 삶의 질에 큰 영향을 미치는 질환을 다루는 것으로, 미국 헬스케어 산업에 매우 중요한 시장입니다. 또한, 이러한 임상시험은 과학적 혁신을 시장 출시 가능한 치료제로 전환하고 동시에 질병 부담을 줄이기 위해 필수적입니다. 이러한 요인들은 예상 기간 동안 시장을 견인할 것으로 예측됩니다.
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 미국의 신경학 임상시험 시장 변수, 동향, 범위
- 시장 계통 전망
- 상위 시장 전망
- 관련/보조 시장 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 시장이 해결해야 할 과제
- 시장 기회
- 연구개발비 분석(2021년-2024년)
- 기술 상황
- 가격 모델 분석
- 임상시험 건수 분석, 2024년
- 2024년 미국의 신경학 임상시험 건수(단계별)
- 2024년 미국의 신경학 임상시험 건수(시험 디자인별)
- 2024년 미국의 신경학 임상시험 건수(주요 적응증별)
- 관세 영향 분석
- 밸류체인 분석
- 공급 동향
- 수요 동향
- 시장 분석 툴
- Porter의 Five Forces 분석
- SWOT 분석에 의한 PESTEL
제4장 미국의 신경학 임상시험 시장 : 단계 추정 및 동향 분석
- 미국의 신경학 임상시험 시장(단계별) : 부문 대시보드
- 미국의 신경학 임상시험 시장(단계별) : 변동 분석
- 단계별, 2021년-2033년
- 1상
- 2상
- 3상
- 4상
제5장 미국의 신경학 임상시험 시장 : 시험 디자인 추정 및 동향 분석
- 미국의 신경학 임상시험 시장(시험 디자인별) : 부문 대시보드
- 미국의 신경학 임상시험 시장, 시험 디자인별 : 변동 분석
- 연구 디자인별, 2021년-2033년
- 개입적
- 관찰적
- 확장 액세스
제6장 미국의 신경학 임상시험 시장 : 적응증 추정 및 동향 분석
- 미국의 신경학 임상시험 시장(적응증별) : 부문 대시보드
- 미국의 신경학 임상시험 시장(적응증별) : 변동 분석
- 증상별, 2021년-2033년
- 알츠하이머병
- 우울증(MDD)
- 파킨슨병(PD)
- 간질
- 뇌졸중
- 외상성 뇌손상(TBI)
- 루게릭병(ALS)
- 헌팅턴병
- 근육 재생
- 기타
제7장 미국의 신경학 임상시험 시장 : 연구 디자인별 적응증 추정 및 동향 분석
- 미국의 신경학 임상시험 시장, 연구 디자인별 적응증 : 부문 대시보드
- 미국의 신경학 임상시험 시장, 연구 디자인별 적응증 : 변동 분석
- 연구 디자인별, 2021년-2033년
- 알츠하이머병
- 알츠하이머병 개입
- 알츠하이머병 관찰
- 알츠하이머병 확대 액세스
- 우울증(MDD)
- 우울증(MDD) 개입
- 우울증(MDD) 관찰
- 우울증(MDD) 확대 액세스
- 파킨슨병(PD)
- 파킨슨병(PD) 개입
- 파킨슨병(PD) 관찰
- 파킨슨병(PD) 확대 액세스
- 간질
- 간질 개입
- 간질 관찰
- 간질 확대 액세스
- 뇌졸중
- 뇌졸중 개입
- 뇌졸중 관찰
- 뇌졸중 확대 액세스
- 외상성 뇌손상(TBI)
- 외상성 뇌손상(TBI) 개입
- 외상성 뇌손상(TBI) 관찰
- 외상성 뇌손상(TBI) 확대 액세스
- 루게릭병(ALS)
- 루게릭병(ALS) 개입
- 루게릭병(ALS) 관찰 연구
- 루게릭병(ALS) 확대 액세스
- 헌팅턴병
- 헌팅턴병 개입
- 헌팅턴병 관찰
- 헌팅턴병 확대 액세스
- 근육 재생
- 줄기 재생 개입
- 근육 재생 관찰
- 근육 재생 확대 액세스
- 기타
- 기타 개입
- 기타 관찰
- 기타 확장 액세스
제8장 미국의 신경학 임상시험 시장 : 단계별 적응증 추정 및 동향 분석
- 미국의 신경학 임상시험 시장, 단계별 적응증 : 부문 대시보드
- 미국의 신경학 임상시험 시장, 단계별 적응증 : 변동 분석
- 단계별, 2021년-2033년
- 알츠하이머병
- 알츠하이머병 1상
- 알츠하이머병 2상
- 알츠하이머병 3상
- 알츠하이머병 4상
- 우울증(MDD)
- 우울증(MDD) 1상
- 우울증(MDD) 2상
- 우울증(MDD) 3상
- 우울증(MDD) 4상
- 파킨슨병(PD)
- 파킨슨병(PD) 1상
- 파킨슨병(PD) 2상
- 파킨슨병(PD) 3상
- 파킨슨병(PD) 4상
- 간질
- 간질 1상
- 간질 2상
- 간질 3상
- 간질 4상
- 뇌졸중
- 뇌졸중 1상
- 뇌졸중 2상
- 뇌졸중 3상
- 뇌졸중 4상
- 외상성뇌손상(TBI)
- 외상성 뇌손상(TBI) 1상
- 외상성 뇌손상(TBI) 2상
- 외상성 뇌손상(TBI) 3상
- 외상성 뇌손상(TBI) 4상
- 루게릭병(ALS)
- 루게릭병(ALS) 1상
- 루게릭병(ALS) 2상
- 루게릭병(ALS) 3상
- 루게릭병(ALS) 4상
- 헌팅턴병
- 헌팅턴병 1상
- 헌팅턴병 2상
- 헌팅턴병 3상
- 헌팅턴병 4상
- 근육 재생
- 근육 재생 1상
- 근육 재생 2상
- 근육 재생 3상
- 근육 재생 4상
- 기타
- 기타 1상
- 기타 2상
- 기타 3상
- 기타 4상
제9장 미국의 신경학 임상시험 시장 : 밸류체인 추정 및 동향 분석
- 미국의 신경학 임상시험 시장(밸류체인별) : 부문 대시보드
- 미국의 신경학 임상시험 시장(밸류체인) : 변동 분석
- 밸류체인별, 2021년-2033년
- 사내
- CRO
- 연구기관 및 임상시험기관
제10장 경쟁 구도
- 시장 진출기업 분류
- 시장 리더
- 신규 기업
- 2024년 시장 평가 분석(히트맵 분석)
- 기업 개요
- Syneos Health
- Icon Plc
- Lindus Health
- AbbVie
- GlaxoSmithKline
- Labcorp Drug Development
- Pfizer
- AstraZeneca
- Biogen
- Eli Lilly
- Alzheon
- BDD Pharma
U.S. Neurology Clinical Trials Market Summary
The U.S. neurology clinical trials market size was estimated at USD 2.53 billion in 2024 and is projected to reach USD 4.47 billion by 2033, growing at a CAGR of 6.59% from 2025 to 2033. The growth of the U.S. market for neurology clinical trials is driven by significant advancements in neuroscience, increasing healthcare spending, and an emphasis on targeted therapies for intricate neurological conditions.
Other factors driving the growth of the U.S. neurology clinical trials industry include increasing patient awareness, regulatory support for orphan drugs and breakthrough therapies, and rising investment in neurology research and development. The rising incidence of neurodegenerative diseases, supported by a well-established clinical research infrastructure, has established the U.S. as a key center for neurology trials. Furthermore, funding from both public and private sectors and strategic partnerships among pharmaceutical companies, contract research organizations (CROs), and academic institutions have played a crucial role in speeding up study timelines and enhancing trial efficiency, further supporting the market.
The increasing prevalence of Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and various rare neurological syndromes has created an increased need for novel treatment options, resulting in a rise in the number of clinical trial activities. These studies are conducted in early and late stages, with more advanced programs concentrating on disease-modifying therapies, neuroprotective agents, and gene-based interventions. In addition, pharmaceutical and biotechnology companies are expanding in-house CRO capabilities to maintain control over study protocols, enhance execution speed, and increase operational efficiency for clinical trials. Besides, a growing number of investigator sites specializing in neurology are further improving patient recruitment accuracy, optimizing trial quality, and shortening enrollment timelines. This blend of in-house capabilities and specialized site expertise boosts the scale and rate of neurological trial delivery across the country.
Moreover, market trends are shifting towards adopting decentralized and hybrid trial models, allowing for broader patient participation and faster data collection. Further, the growing incorporation of advanced neuroimaging techniques, biomarker-based diagnostics, and AI-driven patient selection tools is enhancing the precision of trials and the predictability of outcomes. Furthermore, numerous biopharmaceutical companies are expanding their neurology research portfolios and site networks to strengthen their geographic reach, accelerate regulatory approvals, and better address the unmet needs of patients in underserved areas, further supporting the U.S. neurology clinical trials market.
Thus, the neurology clinical trials market is crucial to the U.S. healthcare industry, as it tackles conditions that heavily influence healthcare costs, workforce productivity, and patients' overall quality of life. Besides, these trials are essential for converting scientific innovations into market-ready treatments while reducing disease burden. Such aforementioned factors are expected to drive the market over the estimated timeframe.
U.S. Neurology Clinical Trials Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. neurology clinical trials market report based onphase, study design, indication, indication by study design, indication by phase, and value chain:
- Phase Outlook (Revenue, USD Million, 2021 - 2033)
- Phase I
- Phase II
- Phase III
- Phase IV
- Study Design Outlook (Revenue, USD Million, 2021 - 2033)
- Interventional
- Observational
- Expanded Access
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Alzheimer's Disease
- Depression (MDD)
- Parkinson's Disease (PD)
- Epilepsy
- Stroke
- Traumatic Brain Injury (TBI)
- Amyotrophic Lateral Sclerosis (ALS)
- Huntington's Disease
- Muscle Regeneration
- Others
- Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)
- Alzheimer's Disease
- Interventional
- Observational
- Expanded Access
- Depression (MDD)
- Interventional
- Observational
- Expanded Access
- Parkinson's Disease (PD)
- Interventional
- Observational
- Expanded Access
- Epilepsy
- Interventional
- Observational
- Expanded Access
- Stroke
- Interventional
- Observational
- Expanded Access
- Traumatic Brain Injury (TBI)
- Interventional
- Observational
- Expanded Access
- Amyotrophic Lateral Sclerosis (ALS)
- Interventional
- Observational
- Expanded Access
- Huntington's Disease
- Interventional
- Observational
- Expanded Access
- Muscle Regeneration
- Interventional
- Observational
- Expanded Access
- Others
- Interventional
- Observational
- Expanded Access
- Indication by Phase Outlook (Revenue, USD Million, 2021 - 2033)
- Alzheimer's Disease
- Phase I
- Phase II
- Phase III
- Phase IV
- Depression (MDD)
- Phase I
- Phase II
- Phase III
- Phase IV
- Parkinson's Disease (PD)
- Phase I
- Phase II
- Phase III
- Phase IV
- Epilepsy
- Phase I
- Phase II
- Phase III
- Phase IV
- Stroke
- Phase I
- Phase II
- Phase III
- Phase IV
- Traumatic Brain Injury (TBI)
- Phase I
- Phase II
- Phase III
- Phase IV
- Amyotrophic Lateral Sclerosis (ALS)
- Phase I
- Phase II
- Phase III
- Phase IV
- Huntington's Disease
- Phase I
- Phase II
- Phase III
- Phase IV
- Muscle Regeneration
- Phase I
- Phase II
- Phase III
- Phase IV
- Others
- Phase I
- Phase II
- Phase III
- Phase IV
- Value Chain Outlook (Revenue, USD Million, 2021 - 2033)
- In-house
- CROs
- Investigator Sites/ Clinical Sites
Table of Contents
Chapter 1. Research Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Study Design
- 1.2.2. Indication
- 1.2.3. Indication by Study Design
- 1.2.4. Indication by Phase
- 1.2.5. Value Chain
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.7.2. Parent Market Analysis
- 1.7.3. Bottom-Up Analysis
- 1.7.4. Multivariate Analysis
- 1.8. List Of Secondary Sources
- 1.9. List Of Abbreviations
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. U.S. Neurology Clinical Trials Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing prevalence of neurological diseases such as Alzheimer's disease, epilepsy, and stroke
- 3.2.1.2. Growing adoption of novel technologies in clinical research
- 3.2.1.3. Rising number of CROs providing U.S. Neurology Clinical research services
- 3.2.1.4. Increasing funding for neurological studies by public organizations
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Increased associated with U.S. Neurology Clinical studies
- 3.2.2.2. High failure rate coupled with patient dropout issues associated with neurological clinical trials
- 3.2.3. Market Challenges
- 3.2.4. Market Opportunities
- 3.2.1. Market Driver Analysis
- 3.3. R&D Spending Analysis (2021-2024)
- 3.4. Technology Landscape
- 3.5. Pricing Model Analysis
- 3.6. Clinical Trial Volume Analysis, 2024
- 3.6.1. Total Number of U.S. Neurology Clinical Trials, by Phase, 2024
- 3.6.2. Total Number of U.S. Neurology Clinical Trials, by Study Design, 2024
- 3.6.3. Total Number of U.S. Neurology Clinical Trials, by Key Indication, 2024
- 3.7. Tariff Impact Analysis
- 3.8. Value Chain Analysis
- 3.8.1. Supply Trends
- 3.8.2. Demand Trends
- 3.9. Market Analysis Tools
- 3.9.1. Porter's Five Forces Analysis
- 3.9.2. PESTEL by SWOT Analysis
Chapter 4. U.S. Neurology Clinical Trials Market: Phase Estimates & Trend Analysis
- 4.1. U.S. Neurology Clinical Trials Market, By Phase: Segment Dashboard
- 4.2. U.S. Neurology Clinical Trials Market, By Phase: Movement Analysis
- 4.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Phase, 2021 - 2033 (USD Million)
- 4.4. Phase I
- 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Phase II
- 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Phase III
- 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7. Phase IV
- 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. Neurology Clinical Trials Market: Study Design Estimates & Trend Analysis
- 5.1. U.S. Neurology Clinical Trials Market, By Study Design: Segment Dashboard
- 5.2. U.S. Neurology Clinical Trials Market, By Study Design: Movement Analysis
- 5.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Study Design, 2021 - 2033 (USD Million)
- 5.4. Interventional
- 5.4.1. Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Observational
- 5.5.1. Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Expanded Access
- 5.6.1. Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. Neurology Clinical Trials Market: Indication Estimates & Trend Analysis
- 6.1. U.S. Neurology Clinical Trials Market, By Indication: Segment Dashboard
- 6.2. U.S. Neurology Clinical Trials Market, By Indication: Movement Analysis
- 6.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
- 6.4. Alzheimer's Disease
- 6.4.1. Alzheimer's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Depression (MDD)
- 6.5.1. Depression (MDD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Parkinson's Disease (PD)
- 6.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Epilepsy
- 6.7.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.8. Stroke
- 6.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.9. Traumatic Brain Injury (TBI)
- 6.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.10. Amyotrophic Lateral Sclerosis (ALS)
- 6.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.11. Huntington's Disease
- 6.11.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.12. Muscle Regeneration
- 6.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.13. Others
- 6.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. U.S. Neurology Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis
- 7.1. U.S. Neurology Clinical Trials Market, Indication by Study Design: Segment Dashboard
- 7.2. U.S. Neurology Clinical Trials Market, Indication by Study Design: Movement Analysis
- 7.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
- 7.4. Alzheimer's Disease
- 7.4.1. Alzheimer's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. Alzheimer's Disease Interventional
- 7.4.2.1. Alzheimer's Disease Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Alzheimer's Disease Observational
- 7.4.3.1. Alzheimer's Disease Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Alzheimer's Disease Expanded Access
- 7.4.4.1. Alzheimer's Disease Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Depression (MDD)
- 7.5.1. Depression (MDD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. Depression (MDD) Interventional
- 7.5.2.1. Depression (MDD) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Depression (MDD) Observational
- 7.5.3.1. Depression (MDD) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. Depression (MDD) Expanded Access
- 7.5.4.1. Depression (MDD) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Parkinson's Disease (PD)
- 7.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Parkinson's Disease (PD) Interventional
- 7.6.2.1. Parkinson's Disease (PD) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. Parkinson's Disease (PD) Observational
- 7.6.3.1. Parkinson's Disease (PD) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. Parkinson's Disease (PD) Expanded Access
- 7.6.4.1. Parkinson's Disease (PD) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Epilepsy
- 7.7.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Epilepsy Interventional
- 7.7.2.1. Epilepsy Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Epilepsy Observational
- 7.7.3.1. Epilepsy Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.4. Epilepsy Expanded Access
- 7.7.4.1. Epilepsy Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Stroke
- 7.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. Stroke Interventional
- 7.8.2.1. Stroke Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Stroke Observational
- 7.8.3.1. Stroke Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. Stroke Expanded Access
- 7.8.4.1. Stroke Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.9. Traumatic Brain Injury (TBI)
- 7.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.9.2. Traumatic Brain Injury (TBI) Interventional
- 7.9.2.1. Traumatic Brain Injury (TBI) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.9.3. Traumatic Brain Injury (TBI) Observational
- 7.9.3.1. Traumatic Brain Injury (TBI) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.9.4. Traumatic Brain Injury (TBI) Expanded Access
- 7.9.4.1. Traumatic Brain Injury (TBI) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.10. Amyotrophic Lateral Sclerosis (ALS)
- 7.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.10.2. Amyotrophic Lateral Sclerosis (ALS) Interventional
- 7.10.2.1. Amyotrophic Lateral Sclerosis (ALS) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.10.3. Amyotrophic Lateral Sclerosis (ALS) Observational
- 7.10.3.1. Amyotrophic Lateral Sclerosis (ALS) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.10.4. Amyotrophic Lateral Sclerosis (ALS) Expanded Access
- 7.10.4.1. Amyotrophic Lateral Sclerosis (ALS) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.11. Huntington's Disease
- 7.11.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.11.2. Huntington's Disease Interventional
- 7.11.2.1. Huntington's Disease Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.11.3. Huntington's Disease Observational
- 7.11.3.1. Huntington's Disease Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.11.4. Huntington's Disease Expanded Access
- 7.11.4.1. Huntington's Disease Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.12. Muscle Regeneration
- 7.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.12.2. Muscle Regeneration Interventional
- 7.12.2.1. Muscle Regeneration Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.12.3. Muscle Regeneration Observational
- 7.12.3.1. Muscle Regeneration Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.12.4. Muscle Regeneration Expanded Access
- 7.12.4.1. Muscle Regeneration Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.13. Others
- 7.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.13.2. Others Interventional
- 7.13.2.1. Others Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.13.3. Others Observational
- 7.13.3.1. Others Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.13.4. Others Expanded Access
- 7.13.4.1. Others Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. U.S. Neurology Clinical Trials Market: Indication by Phase Estimates & Trend Analysis
- 8.1. U.S. Neurology Clinical Trials Market, Indication by Phase: Segment Dashboard
- 8.2. U.S. Neurology Clinical Trials Market, Indication by Phase: Movement Analysis
- 8.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, Indication by Phase, 2021 - 2033 (USD Million)
- 8.4. Alzheimer's Disease
- 8.4.1. Alzheimer's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.2. Alzheimer's Disease Phase I
- 8.4.2.1. Alzheimer's Disease Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Alzheimer's Disease Phase II
- 8.4.3.1. Alzheimer's Disease Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Alzheimer's Disease Phase III
- 8.4.4.1. Alzheimer's Disease Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.5. Alzheimer's Disease Phase IV
- 8.4.5.1. Alzheimer's Disease Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5. Depression (MDD)
- 8.5.1. Depression (MDD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. Depression (MDD) Phase I
- 8.5.2.1. Depression (MDD) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Depression (MDD) Phase II
- 8.5.3.1. Depression (MDD) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. Depression (MDD) Phase III
- 8.5.4.1. Depression (MDD) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Depression (MDD) Phase IV
- 8.5.5.1. Depression (MDD) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6. Parkinson's Disease (PD)
- 8.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Parkinson's Disease (PD) Phase I
- 8.6.2.1. Parkinson's Disease (PD) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. Parkinson's Disease (PD) Phase II
- 8.6.3.1. Parkinson's Disease (PD) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.4. Parkinson's Disease (PD) Phase III
- 8.6.4.1. Parkinson's Disease (PD) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Parkinson's Disease (PD) Phase IV
- 8.6.5.1. Parkinson's Disease (PD) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7. Epilepsy
- 8.7.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. Epilepsy Phase I
- 8.7.2.1. Epilepsy Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Epilepsy Phase II
- 8.7.3.1. Epilepsy Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.4. Epilepsy Phase III
- 8.7.4.1. Epilepsy Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.5. Epilepsy Phase IV
- 8.7.5.1. Epilepsy Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8. Stroke
- 8.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.2. Stroke Phase I
- 8.8.2.1. Stroke Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.3. Stroke Phase II
- 8.8.3.1. Stroke Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.4. Stroke Phase III
- 8.8.4.1. Stroke Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.5. Stroke Phase IV
- 8.8.5.1. Stroke Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.9. Traumatic Brain Injury (TBI)
- 8.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.9.2. Traumatic Brain Injury (TBI) Phase I
- 8.9.2.1. Traumatic Brain Injury (TBI) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.9.3. Traumatic Brain Injury (TBI) Phase II
- 8.9.3.1. Traumatic Brain Injury (TBI) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.9.4. Traumatic Brain Injury (TBI) Phase III
- 8.9.4.1. Traumatic Brain Injury (TBI) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.9.5. Traumatic Brain Injury (TBI) Phase IV
- 8.9.5.1. Traumatic Brain Injury (TBI) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.10. Amyotrophic Lateral Sclerosis (ALS)
- 8.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.10.2. Amyotrophic Lateral Sclerosis (ALS) Phase I
- 8.10.2.1. Amyotrophic Lateral Sclerosis (ALS) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.10.3. Amyotrophic Lateral Sclerosis (ALS) Phase II
- 8.10.3.1. Amyotrophic Lateral Sclerosis (ALS) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.10.4. Amyotrophic Lateral Sclerosis (ALS) Phase III
- 8.10.4.1. Amyotrophic Lateral Sclerosis (ALS) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.10.5. Amyotrophic Lateral Sclerosis (ALS) Phase IV
- 8.10.5.1. Amyotrophic Lateral Sclerosis (ALS) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.11. Huntington's Disease
- 8.11.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.11.2. Huntington's Disease Phase
- 8.11.2.1. Huntington's Disease Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.11.3. Huntington's Disease Phase II
- 8.11.3.1. Huntington's Disease Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.11.4. Huntington's Disease Phase III
- 8.11.4.1. Huntington's Disease Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.11.5. Huntington's Disease Phase IV
- 8.11.5.1. Huntington's Disease Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.12. Muscle Regeneration
- 8.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.12.2. Muscle Regeneration Phase I
- 8.12.2.1. Muscle Regeneration Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.12.3. Muscle Regeneration Phase II
- 8.12.3.1. Muscle Regeneration Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.12.4. Muscle Regeneration Phase III
- 8.12.4.1. Muscle Regeneration Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.12.5. Muscle Regeneration Phase IV
- 8.12.5.1. Muscle Regeneration Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.13. Others
- 8.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.13.2. Others Phase I
- 8.13.2.1. Others Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.13.3. Others Phase II
- 8.13.3.1. Others Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.13.4. Others Phase III
- 8.13.4.1. Others Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.13.5. Others Phase IV
- 8.13.5.1. Others Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. U.S. Neurology Clinical Trials Market: Value Chain Estimates & Trend Analysis
- 9.1. U.S. Neurology Clinical Trials Market, By Value Chain: Segment Dashboard
- 9.2. U.S. Neurology Clinical Trials Market, By Value Chain: Movement Analysis
- 9.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Value Chain, 2021 - 2033 (USD Million)
- 9.4. In-house
- 9.4.1. In-house Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5. CROs
- 9.5.1. CROs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6. Investigator Sites/Clinical Sites
- 9.6.1. Investigator Sites/Clinical Sites Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Market Participant Categorization
- 10.1.1. Market Leaders
- 10.1.2. Emerging Players
- 10.2. Market Assessment Analysis, 2024 (Heat Map Analysis)
- 10.3. Company Profiles
- 10.3.1. Syneos Health
- 10.3.1.1. Company Overview
- 10.3.1.2. Financial Performance
- 10.3.1.3. Service Benchmarking
- 10.3.1.4. Strategic Initiatives
- 10.3.2. Icon Plc
- 10.3.2.1. Company Overview
- 10.3.2.2. Financial Performance
- 10.3.2.3. Service Benchmarking
- 10.3.2.4. Strategic Initiatives
- 10.3.3. Lindus Health
- 10.3.3.1. Company Overview
- 10.3.3.2. Financial Performance
- 10.3.3.3. Service Benchmarking
- 10.3.3.4. Strategic Initiatives
- 10.3.4. AbbVie
- 10.3.4.1. Company Overview
- 10.3.4.2. Financial Performance
- 10.3.4.3. Service Benchmarking
- 10.3.4.4. Strategic Initiatives
- 10.3.5. GlaxoSmithKline
- 10.3.5.1. Company Overview
- 10.3.5.2. Financial Performance
- 10.3.5.3. Service Benchmarking
- 10.3.5.4. Strategic Initiatives
- 10.3.6. Labcorp Drug Development
- 10.3.6.1. Company Overview
- 10.3.6.2. Financial Performance
- 10.3.6.3. Service Benchmarking
- 10.3.6.4. Strategic Initiatives
- 10.3.7. Pfizer
- 10.3.7.1. Company Overview
- 10.3.7.2. Financial Performance
- 10.3.7.3. Service Benchmarking
- 10.3.7.4. Strategic Initiatives
- 10.3.8. AstraZeneca
- 10.3.8.1. Company Overview
- 10.3.8.2. Financial Performance
- 10.3.8.3. Service Benchmarking
- 10.3.8.4. Strategic Initiatives
- 10.3.9. Biogen
- 10.3.9.1. Company Overview
- 10.3.9.2. Financial Performance
- 10.3.9.3. Service Benchmarking
- 10.3.9.4. Strategic Initiatives
- 10.3.10. Eli Lilly
- 10.3.10.1. Company Overview
- 10.3.10.2. Financial Performance
- 10.3.10.3. Service Benchmarking
- 10.3.10.4. Strategic Initiatives
- 10.3.11. Alzheon
- 10.3.11.1. Company Overview
- 10.3.11.2. Financial Performance
- 10.3.11.3. Service Benchmarking
- 10.3.11.4. Strategic Initiatives
- 10.3.12. BDD Pharma
- 10.3.12.1. Company Overview
- 10.3.12.2. Financial Performance
- 10.3.12.3. Service Benchmarking
- 10.3.12.4. Strategic Initiatives
- 10.3.1. Syneos Health
샘플 요청 목록